<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182386</url>
  </required_header>
  <id_info>
    <org_study_id>Scandinavian PVE study</org_study_id>
    <nct_id>NCT04182386</nct_id>
  </id_info>
  <brief_title>Scandinavian Cohort Study for Optimal Use of Portal Vein Embolization</brief_title>
  <official_title>Scandinavian Cohort Study for Optimal Use of Portal Vein Embolization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several aspects on the use of portal vein embolization (PVE) are poorly studied and todays
      recommendations are based on low-grade evidence. In this Scandinavian multicenter cohort
      study we will study some of the controversial aspects on the use of PVE to try to provide
      clearer answers on its optimal use. Six tertiary university hospital hepatobiliary units in
      Sweden, Norway and Denmark participate and contribute with all PVE procedures performed at
      their units during the study period. We will then study several aspects PVE technique in
      relation to induced hypertrophy and surgical outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2012</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Future liver remnant hypertrophy</measure>
    <time_frame>Based on radiology around 4 weeks before and after intervention</time_frame>
    <description>Increase in future liver remnant, (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of segment 4 embolization on hypertrophy</measure>
    <time_frame>Based on radiology around 4 weeks before and after intervention</time_frame>
    <description>Increase in future liver remnant (%) dependeing on if segment 4 is embolized or not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of hyperbilirubinemia on hypertrophy</measure>
    <time_frame>Based on radiology around 4 weeks before and after intervention</time_frame>
    <description>Increase in future liver remnant (%) dependeing on the levels of bilirubin before portal vein embolization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of sarcopenia on hypertrophy</measure>
    <time_frame>Based on radiology around 4 weeks before and after intervention</time_frame>
    <description>Increase in future liver remnant (%) dependeing on the level of sarcopenia before portal vein embolization.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>rPVE</arm_group_label>
    <description>Right portal vein embolization. All patients subjected to selective right portal vein embolization prior to planned hepatobiliary surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rPVE+S4</arm_group_label>
    <description>Right portal vein embolization including segment 4 portal vein branches. All patients subjected to selective right portal vein embolization including segment 4 portal vein branches prior to planned hepatobiliary surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Portal vein embolization</intervention_name>
    <description>Selective preoperative portal vein embolization</description>
    <arm_group_label>rPVE</arm_group_label>
    <arm_group_label>rPVE+S4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Scandinavian patients subjected to PVE at 6 hepatobiliary centers during the study period.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Right-sided PVE

        Exclusion Criteria:

          -  Left-sided PVE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernesto Sparrelid, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ernesto Sparrelid, MD PhD</last_name>
    <phone>+46-708-880787</phone>
    <email>ernesto.sparrelid@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Gilg, MD PhD</last_name>
    <phone>+46-702-677722</phone>
    <email>stefan.gilg@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Sparrelid, MD PhD</last_name>
      <email>ernesto.sparrelid@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Ernesto Sparrelid</investigator_full_name>
    <investigator_title>Acting Head of HPB Surgery, MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available to other researchers on demand.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be made available to other researchers on demand.</ipd_time_frame>
    <ipd_access_criteria>Data will be made available to other researchers on demand.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

